Moffitt Cancer Center Logo
 

Pamela Joy Hodul, MD

Where You Are:
Pamela Joy Hodul, MD

Assistant Member

"We are interested in identifying novel molecular targets involved in the development and progression of pancreatic and neuroendocrine tumors."

Office  (813) 745-1277

Education And Training
  • Research Fellow, H. Lee Moffitt Cancer Center & Research Institute, 2006 - Surgical Oncology
  • Clinical Fellow, H. Lee Moffitt Cancer Center & Research Institute, 2005 - Surgical Oncology
  • Intern & Resident, Loyola University Chicago Stritch School of Medicine, 2003 - Surgery
  • MD, Loyola University Chicago Stritch School of Medicine, 1998
  • BS, University of Michigan, 1993 - Neuropsychology


Our research interests center on pancreatic cancer and tumors of neuroendocrine origin are amongst the most challenging neoplasms to diagnose and treat. Due to their relative rarity and complex pathogenesis, few advances in research have translated into improved clinical outcome. Our work is currently focused on studying tumor biology and signaling mechanisms as they relate to proliferation and development of metastasis. In particular, we are interested in identifying novel molecular targets involved in the development and progression of pancreatic and neuroendocrine tumors. In collaboration with the departments of Drug Discovery and Experimental Therapeutics, we will design and develop new anticancer drugs targeting oncogenic signaling pathways vital to tumor progression, and translate these discoveries into new treatments which are tested in hypothesis-driven clinical trials.

  • Mellon EA, Springett GM, Hoffe SE, Hodul P, Malafa MP, Meredith KL, Fulp WJ, Zhao X, Shridhar R. Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer. 2014 Apr;120(8):1171-1177. Pubmedid: 24390779.
  • Toloza E, Sobky C, Cheng A, Chai C, Smithson I, Brown L, Moodie C, Garrett J, Parsons C, Hodul P, Malafa M. Robotic-assisted video-thoracoscopic closure of pancreatico-pleural fistula: a case report. Chest. 2014 Mar;145(3 Suppl):36A. Pubmedid: 24638527.
  • Hodul PJ, Dong Y, Husain K, Pimiento JM, Chen J, Zhang A, Francois R, Pledger WJ, Coppola D, Sebti SM, Chen DT, Malafa MP. Vitamin E δ-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanism. PLoS One. 2013 Aug;8(2):e52526. Pubmedid: 23393547. Pmcid: PMC3564846.
  • Chuong MD, Springett GM, Freilich JM, Park CK, Weber JM, Mellon EA, Hodul PJ, Malafa MP, Meredith KL, Hoffe SE, Shridhar R. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013 Jul;86(3):516-522. Pubmedid: 23562768.
  • Wong J, Weber J, A Centeno B, Vignesh S, Harris CL, Klapman JB, Hodul P. High-Grade Dysplasia and Adenocarcinoma Are Frequent in Side-Branch Intraductal Papillary Mucinous Neoplasm Measuring Less than 3 cm on Endoscopic Ultrasound. J Gastrointest Surg. 2013 Jan;17(1):78-85. Pubmedid: 22948841.
  • Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, Kvols LK. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012 Aug;256(2):321-325. Pubmedid: 22415420.
  • Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011 Aug;104(2):155-161. Pubmedid: 21520097. Pmcid: PMC3347705.
  • Chuong MD, Hayman TJ, Patel MR, Russell MS, Malafa MP, Hodul PJ, Springett GM, Choi J, Shridhar R, Hoffe SE. Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer. Gastrointest Cancer Res. 2011 Jul;4(4):128-134. Pubmedid: 22368736. Pmcid: PMC3283109.
  • Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, Henderson-Jackson EB, Hodul P, Bui MM, Nasir NA, Hakam A, Malafa MP, Yeatman TJ, Coppola D, Kvols LK. RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. Pancreas. 2011 May;40(4):627-633. Pubmedid: 21499216.
  • Helm J, Centeno B, Coppola D, Druta M, Park J, Chen D, Hodul P, Kvols LK, Yeatman T, Carey L, Karl R, Malafa M. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control. 2008 Oct;15(4):288-294. Pubmedid: 18813196.
  • Hodul P, Strosberg J, Kvols L. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated. Cancer Control. 2008 Oct;15(4):314-321. Pubmedid: 18813199.
  • Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008 May;2(3):113-125. Pubmedid: 19259290.
  • Park J, Helm J, Zheng W, Ly Q, Hodul P, Centeno B, Malafa M. Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancer. Pancreas. 2008 May;36(4):e32-e39. Pubmedid: 18437076.
  • Hodul P, Yeatman T. TNM staging is obsolete. J Surg Oncol. 2006 Dec;95(1):8-9. Pubmedid: 17192885.
  • Hodul P, Malafa M, Choi J, Kvols L. The role of cytoreductive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control. 2006 Jan;13(1):61-71. Pubmedid: 16508628.
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer